Alternative application of Tau protein in Creutzfeldt-Jakob disease diagnosis: Improvement for weakly positive 14-3-3 protein in the laboratory
暂无分享,去创建一个
S. Y. Kim | Myung-Koo Lee | Jeongmin Lee | Y. Ju | SeongSoo A. An | K. Hwang | J. Hyeon | Sol Moe Lee | J. Park
[1] A. Fournier,et al. Neuroprotective Function of 14-3-3 Proteins in Neurodegeneration , 2013, BioMed research international.
[2] A. Bizzi,et al. A comparison of tau and 14-3-3 protein in the diagnosis of Creutzfeldt-Jakob disease , 2012, Neurology.
[3] K. Satoh,et al. High sensitivity of an ELISA kit for detection of the gamma-isoform of 14-3-3 proteins: usefulness in laboratory diagnosis of human prion disease , 2011, BMC neurology.
[4] A. Cagnin,et al. Cerebrospinal Fluid Markers in Sporadic Creutzfeldt-Jakob Disease , 2011, International Journal of Molecular Sciences.
[5] Xiongwei Zhu,et al. Cell cycle deregulation in the neurons of Alzheimer's disease. , 2011, Results and problems in cell differentiation.
[6] W. Zhou,et al. Elevated Levels of Tau Protein in Cerebrospinal Fluid of Patients With Probable Creutzfeldt-Jakob Disease , 2010, The American journal of the medical sciences.
[7] H. Kretzschmar,et al. 14-3-3 CSF levels in sporadic Creutzfeldt–Jakob disease differ across molecular subtypes , 2009, Neurobiology of Aging.
[8] P. Johannsen,et al. The diagnostic efficiency of biomarkers in sporadic Creutzfeldt-Jakob disease compared to Alzheimer's disease , 2009, Neurobiology of Aging.
[9] C. Begue,et al. Updated clinical diagnostic criteria for sporadic Creutzfeldt-Jakob disease , 2009, Brain : a journal of neurology.
[10] M. Takeda,et al. Phosphorylation of tau at Ser214 mediates its interaction with 14‐3‐3 protein: implications for the mechanism of tau aggregation , 2009, Journal of neurochemistry.
[11] K. Eguchi,et al. Total Tau Protein in Cerebrospinal Fluid and Diffusion-Weighted MRI as an Early Diagnostic Marker for Creutzfeldt-Jakob Disease , 2007, Dementia and Geriatric Cognitive Disorders.
[12] H. Monaco,et al. Detection of CSF 14-3-3 protein in Guillain–Barré syndrome , 2006, Neurology.
[13] K. Eguchi,et al. 14-3-3 Protein, Total Tau and Phosphorylated Tau in Cerebrospinal Fluid of Patients with Creutzfeldt-Jakob Disease and Neurodegenerative Disease in Japan , 2006, Cellular and Molecular Neurobiology.
[14] K. Blennow,et al. Dissociation between CSF total tau and tau protein phosphorylated at threonine 231 in Creutzfeldt–Jakob disease , 2006, Neurobiology of Aging.
[15] K. Blennow,et al. Diagnostic value of 14-3-3beta immunoblot and T-tau/P-tau ratio in clinically suspected Creutzfeldt-Jakob disease. , 2005, International journal of molecular medicine.
[16] H. Monaco,et al. Phosphorylated 14-3-3ζ protein in the CSF of neuroleptic-treated patients , 2005, Neurology.
[17] J. Wiltfang,et al. Follow-Up Investigations of Tau Protein and S-100B Levels in Cerebrospinal Fluid of Patients with Creutzfeldt-Jakob Disease , 2005, Dementia and Geriatric Cognitive Disorders.
[18] R. Castellani,et al. Sensitivity of 14-3-3 protein test varies in subtypes of sporadic Creutzfeldt-Jakob disease , 2004, Neurology.
[19] C. MacKintosh,et al. Dynamic interactions between 14-3-3 proteins and phosphoproteins regulate diverse cellular processes. , 2004, The Biochemical journal.
[20] Jesus Avila,et al. Role of tau protein in both physiological and pathological conditions. , 2004, Physiological reviews.
[21] J. Martín,et al. A prospective study of CSF markers in 250 patients with possible Creutzfeldt–Jakob disease , 2003, Journal of neurology, neurosurgery, and psychiatry.
[22] N. Barbaro,et al. Challenging the clinical utility of the 14-3-3 protein for the diagnosis of sporadic Creutzfeldt-Jakob disease. , 2003, Archives of neurology.
[23] H. Paudel,et al. 14-3-3 Connects Glycogen Synthase Kinase-3β to Tau within a Brain Microtubule-associated Tau Phosphorylation Complex* , 2003, The Journal of Biological Chemistry.
[24] H. Vanderstichele,et al. Phospho-tau/total tau ratio in cerebrospinal fluid discriminates Creutzfeldt–Jakob disease from other dementias , 2003, Molecular Psychiatry.
[25] R. Sánchez-Valle,et al. 14-3-3 protein isoforms and atypical patterns of the 14-3-3 assay in the diagnosis of Creutzfeldt–Jakob disease , 2002, Neuroscience Letters.
[26] J. Wiltfang,et al. Tau protein and 14-3-3 protein in the differential diagnosis of Creutzfeldt–Jakob disease , 2002, Neurology.
[27] A. Lowman,et al. Misleading results with the 14-3-3 assay for the diagnosis of Creutzfeldt–Jakob disease , 2001, Neurology.
[28] C. Gibbs,et al. An enzyme‐linked immunosorbent assay to quantify 14‐3‐3 proteins in the cerebrospinal fluid of suspected Creutzfeldt‐Jakob disease patients , 2000, Annals of neurology.
[29] S. Masters,et al. 14-3-3 proteins: structure, function, and regulation. , 2000, Annual review of pharmacology and toxicology.
[30] Y. Kim,et al. Molecular analysis of prion protein gene (PRNP) in Korean patients with Creutzfeldt-Jakob disease. , 1998, Journal of Korean medical science.
[31] C. Der,et al. 14-3-3 ζ Negatively Regulates Raf-1 Activity by Interactions with the Raf-1 Cysteine-rich Domain* , 1997, The Journal of Biological Chemistry.
[32] J Q Trojanowski,et al. Molecular basis of phenotypic variability in sporadc creudeldt‐jakob disease , 1996, Annals of neurology.